819 related articles for article (PubMed ID: 2990123)
1. [Development of a numerically additive combined vaccine against tetanus and smallpox].
Mayr A; Baljer G; Wagner C; Sailer J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
[TBL] [Abstract][Full Text] [Related]
2. [An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author's transl)].
Hochstein-Mintzel V; Hänichen T; Huber HC; Stickl H
Zentralbl Bakteriol Orig A; 1975; 230(3):283-97. PubMed ID: 1146441
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
4. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain.
Hsieh SM; Chen SY; Sheu GC; Hung MN; Chou WH; Chang SC; Hsu KH
Vaccine; 2006 Jan; 24(4):510-5. PubMed ID: 16139395
[TBL] [Abstract][Full Text] [Related]
6. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.
Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
Vaccine; 2008 Mar; 26(14):1794-804. PubMed ID: 18336966
[TBL] [Abstract][Full Text] [Related]
7. [The immunogenic capacity of soluble "vaccinia" antigen (fractionated smallpox vaccine) administered simultaneously with inactivated typhoid vaccine and with purified and concentrated tetanus anatoxin].
Mihăilescu R; Dimache G; Velea V; Stoean C; Croitoru M; Durbacă S; Chirescu N
Arch Roum Pathol Exp Microbiol; 1989; 48(2):151-6. PubMed ID: 2699409
[TBL] [Abstract][Full Text] [Related]
8. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
9. Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants.
Hartnack S; Essbauer S; Truyen U
Zoonoses Public Health; 2008; 55(2):99-105. PubMed ID: 18234028
[TBL] [Abstract][Full Text] [Related]
10. Mouse neurotoxicity test for vaccinia-based smallpox vaccines.
Li Z; Rubin SA; Taffs RE; Merchlinsky M; Ye Z; Carbone KM
Vaccine; 2004 Mar; 22(11-12):1486-93. PubMed ID: 15063573
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
12. Oral immunization against smallpox.
Hochstein-Mintzel V; Stickl H; Huber HC
Dev Biol Stand; 1976; 33():260-6. PubMed ID: 182585
[TBL] [Abstract][Full Text] [Related]
13. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
15. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
16. Smallpox vaccination and bioterrorism with pox viruses.
Mayr A
Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):423-30. PubMed ID: 12818626
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of human immunological responses to vaccinia virus.
Harrop R; Ryan MG; Golding H; Redchenko I; Carroll MW
Methods Mol Biol; 2004; 269():243-66. PubMed ID: 15114020
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of cynomolgus peripheral blood lymphocytes with tetanus toxoid and smallpox vaccine.
Loggen HG; Baerends-Verburg JL; Kreeftenberg JG
J Med Primatol; 1983; 12(4):192-200. PubMed ID: 6680145
[TBL] [Abstract][Full Text] [Related]
19. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.
Meseda CA; Weir JP
Future Microbiol; 2010 Sep; 5(9):1367-82. PubMed ID: 20860482
[TBL] [Abstract][Full Text] [Related]
20. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
